{"pmid":32320852,"title":"Deja vu: stimulating open drug discovery for SARS-CoV-2.","text":["Deja vu: stimulating open drug discovery for SARS-CoV-2.","In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of deja vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery.","Drug Discov Today","Ekins, Sean","Mottin, Melina","Ramos, Paulo R P S","Sousa, Bruna K P","Neves, Bruno Junior","Foil, Daniel H","Zorn, Kimberley M","Braga, Rodolpho C","Coffee, Megan","Southan, Christopher","Puhl, Ana C","Andrade, Carolina Horta","32320852"],"abstract":["In the past decade we have seen two major Ebola virus outbreaks in Africa, the Zika virus in Brazil and the Americas and the current pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). There is a strong sense of deja vu because there are still no effective treatments. In the COVID-19 pandemic, despite being a new virus, there are already drugs suggested as active in in vitro assays that are being repurposed in clinical trials. Promising SARS-CoV-2 viral targets and computational approaches are described and discussed. Here, we propose, based on open antiviral drug discovery approaches for previous outbreaks, that there could still be gaps in our approach to drug discovery."],"journal":"Drug Discov Today","authors":["Ekins, Sean","Mottin, Melina","Ramos, Paulo R P S","Sousa, Bruna K P","Neves, Bruno Junior","Foil, Daniel H","Zorn, Kimberley M","Braga, Rodolpho C","Coffee, Megan","Southan, Christopher","Puhl, Ana C","Andrade, Carolina Horta"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32320852","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.drudis.2020.03.019","keywords":["covid-19","coronavirus","sars-cov-2","docking","drug discovery","machine learning","open science."],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Zika","Brazil","vitro assays"],"countries":["Brazil"],"countries_codes":["BRA|Brazil"],"_version_":1664815087650603008,"score":8.518259,"similar":[{"pmid":32325767,"title":"COVID-19 Drug Discovery Using Intensive Approaches.","text":["COVID-19 Drug Discovery Using Intensive Approaches.","Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable.","Int J Mol Sci","Asai, Ayumu","Konno, Masamitsu","Ozaki, Miyuki","Otsuka, Chihiro","Vecchione, Andrea","Arai, Takahiro","Kitagawa, Toru","Ofusa, Ken","Yabumoto, Masami","Hirotsu, Takaaki","Taniguchi, Masateru","Eguchi, Hidetoshi","Doki, Yuichiro","Ishii, Hideshi","32325767"],"abstract":["Since the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was reported in China during December 2019, the coronavirus disease 2019 (COVID-19) has spread on a global scale, causing the World Health Organization (WHO) to issue a warning. While novel vaccines and drugs that target SARS-CoV-2 are under development, this review provides information on therapeutics which are under clinical trials or are proposed to antagonize SARS-CoV-2. Based on the information gained from the responses to other RNA coronaviruses, including the strains that cause severe acute respiratory syndrome (SARS)-coronaviruses and Middle East respiratory syndrome (MERS), drug repurposing might be a viable strategy. Since several antiviral therapies can inhibit viral replication cycles or relieve symptoms, mechanisms unique to RNA viruses will be important for the clinical development of antivirals against SARS-CoV-2. Given that several currently marketed drugs may be efficient therapeutic agents for severe COVID-19 cases, they may be beneficial for future viral pandemics and other infections caused by RNA viruses when standard treatments are unavailable."],"journal":"Int J Mol Sci","authors":["Asai, Ayumu","Konno, Masamitsu","Ozaki, Miyuki","Otsuka, Chihiro","Vecchione, Andrea","Arai, Takahiro","Kitagawa, Toru","Ofusa, Ken","Yabumoto, Masami","Hirotsu, Takaaki","Taniguchi, Masateru","Eguchi, Hidetoshi","Doki, Yuichiro","Ishii, Hideshi"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32325767","week":"202017|Apr 20 - Apr 26","doi":"10.3390/ijms21082839","keywords":["covid-19","coronavirus","drug discovery","drug repositioning","infection"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664996914738757632,"score":182.76482},{"pmid":32324951,"title":"Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics.","text":["Drug Development and Medicinal Chemistry Efforts Toward SARS-Coronavirus and Covid-19 Therapeutics.","The COVID-19 pandemic caused by SARS-CoV-2 infection is spreading at an alarming rate and has created an unprecedented health emergency around the globe. There is no effective vaccine or approved drug treatment against COVID-19 and other pathogenic coronaviruses. The development of antiviral agents is an urgent priority. Biochemical events critical to the coronavirus replication cycle provided a number of attractive targets for drug development. These include, spike protein for binding to host cell surface receptor, proteolytic enzymes that are essential for processing polyproteins into mature viruses, and RNA dependent RNA polymerase for RNA replication. There has been much ground work for drug discovery and development against these targets. Also, high throughput screening efforts led to identification of diverse lead structures, including product-derived molecules. The present review highlights past and present drug discovery and medicinal chemistry approaches against SARS-CoV, MERS-CoV and COVID-19 targets. The review will stimulate further research and will be a useful guide to the development of effective therapy against COVID-19 and other pathogenic coronaviruses.","ChemMedChem","Ghosh, Arun K","Brindisi, Margherita","Shahabi, Dana","Chapman, Mackenzie E","Mesecar, Andrew D","32324951"],"abstract":["The COVID-19 pandemic caused by SARS-CoV-2 infection is spreading at an alarming rate and has created an unprecedented health emergency around the globe. There is no effective vaccine or approved drug treatment against COVID-19 and other pathogenic coronaviruses. The development of antiviral agents is an urgent priority. Biochemical events critical to the coronavirus replication cycle provided a number of attractive targets for drug development. These include, spike protein for binding to host cell surface receptor, proteolytic enzymes that are essential for processing polyproteins into mature viruses, and RNA dependent RNA polymerase for RNA replication. There has been much ground work for drug discovery and development against these targets. Also, high throughput screening efforts led to identification of diverse lead structures, including product-derived molecules. The present review highlights past and present drug discovery and medicinal chemistry approaches against SARS-CoV, MERS-CoV and COVID-19 targets. The review will stimulate further research and will be a useful guide to the development of effective therapy against COVID-19 and other pathogenic coronaviruses."],"journal":"ChemMedChem","authors":["Ghosh, Arun K","Brindisi, Margherita","Shahabi, Dana","Chapman, Mackenzie E","Mesecar, Andrew D"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324951","week":"202017|Apr 20 - Apr 26","doi":"10.1002/cmdc.202000223","keywords":["covid-19","coronavirus","drug discovery","sars-cov","protease inhibitors"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664895932679847937,"score":169.77177},{"pmid":32272481,"title":"Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","text":["Structure of M(pro) from COVID-19 virus and discovery of its inhibitors.","A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available.","Nature","Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao","32272481"],"abstract":["A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan(1-4). Currently there are no targeted therapeutics and effective treatment options remain very limited. In order to rapidly discover lead compounds for clinical use, we initiated a program of combined structure-assisted drug design, virtual drug screening and high-throughput screening to identify new drug leads that target the COVID-19 virus main protease (M(pro)). M(pro) is a key CoV enzyme, which plays a pivotal role in mediating viral replication and transcription, making it an attractive drug target for this virus(5,6). Here, we identified a mechanism-based inhibitor, N3, by computer-aided drug design and subsequently determined the crystal structure of COVID-19 virus M(pro) in complex with this compound. Next, through a combination of structure-based virtual and high-throughput screening, we assayed over 10,000 compounds including approved drugs, drug candidates in clinical trials, and other pharmacologically active compounds as inhibitors of M(pro). Six of these compounds inhibited M(pro) with IC50 values ranging from 0.67 to 21.4 muM. Ebselen also exhibited promising antiviral activity in cell-based assays. Our results demonstrate the efficacy of this screening strategy, which can lead to the rapid discovery of drug leads with clinical potential in response to new infectious diseases for which no specific drugs or vaccines are available."],"journal":"Nature","authors":["Jin, Zhenming","Du, Xiaoyu","Xu, Yechun","Deng, Yongqiang","Liu, Meiqin","Zhao, Yao","Zhang, Bing","Li, Xiaofeng","Zhang, Leike","Peng, Chao","Duan, Yinkai","Yu, Jing","Wang, Lin","Yang, Kailin","Liu, Fengjiang","Jiang, Rendi","Yang, Xinglou","You, Tian","Liu, Xiaoce","Yang, Xiuna","Bai, Fang","Liu, Hong","Liu, Xiang","Guddat, Luke W","Xu, Wenqing","Xiao, Gengfu","Qin, Chengfeng","Shi, Zhengli","Jiang, Hualiang","Rao, Zihe","Yang, Haitao"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32272481","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41586-020-2223-y","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"e_drugs":["ebselen"],"_version_":1664637315706781698,"score":159.13312},{"pmid":32317408,"title":"Perspectives for repurposing drugs for the coronavirus disease 2019.","text":["Perspectives for repurposing drugs for the coronavirus disease 2019.","The newly emerged 2019 novel coronavirus (CoV), named as severe acute respiratory syndrome CoV-2 (SARS-CoV-2), like SARS-CoV (now, SARS-CoV-1) and Middle East respiratory syndrome CoV (MERS-CoV), has been associated with high infection rates with over 36,405 deaths. In the absence of approved marketed drugs against coronaviruses, the treatment and management of this novel CoV disease (COVID-19) worldwide is a challenge. Drug repurposing that has emerged as an effective drug discovery approach from earlier approved drugs could reduce the time and cost compared to de novo drug discovery. Direct virus-targeted antiviral agents target specific nucleic acid or proteins of the virus while host-based antivirals target either the host innate immune responses or the cellular machineries that are crucial for viral infection. Both the approaches necessarily interfere with viral pathogenesis. Here we summarize the present status of both virus-based and host-based drug repurposing perspectives for coronaviruses in general and the SARS-CoV-2 in particular.","Indian J Med Res","Cherian, Sarah S","Agrawa, Megha","Basu, Atanu","Abraham, Priya","Gangakhedkar, Raman R","Bhargava, Balram","32317408"],"abstract":["The newly emerged 2019 novel coronavirus (CoV), named as severe acute respiratory syndrome CoV-2 (SARS-CoV-2), like SARS-CoV (now, SARS-CoV-1) and Middle East respiratory syndrome CoV (MERS-CoV), has been associated with high infection rates with over 36,405 deaths. In the absence of approved marketed drugs against coronaviruses, the treatment and management of this novel CoV disease (COVID-19) worldwide is a challenge. Drug repurposing that has emerged as an effective drug discovery approach from earlier approved drugs could reduce the time and cost compared to de novo drug discovery. Direct virus-targeted antiviral agents target specific nucleic acid or proteins of the virus while host-based antivirals target either the host innate immune responses or the cellular machineries that are crucial for viral infection. Both the approaches necessarily interfere with viral pathogenesis. Here we summarize the present status of both virus-based and host-based drug repurposing perspectives for coronaviruses in general and the SARS-CoV-2 in particular."],"journal":"Indian J Med Res","authors":["Cherian, Sarah S","Agrawa, Megha","Basu, Atanu","Abraham, Priya","Gangakhedkar, Raman R","Bhargava, Balram"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317408","week":"202017|Apr 20 - Apr 26","doi":"10.4103/ijmr.IJMR_585_20","keywords":["coronavirus - covid-19 - drugs - host-based - repurposing - severe acute respiratory syndrome coronavirus 2 - virus-based"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087696740352,"score":155.69336},{"pmid":32306836,"title":"Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment.","text":["Novel 2019 Coronavirus Structure, Mechanism of Action, Antiviral drug promises and rule out against its treatment.","In the past two decades, the world has faced several infectious disease outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms of economic disruption, the strain on local and global public health. Most recently, the global outbreak of novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 is a newly discovered virus from the coronavirus family in Wuhan city, China, known to be a great threat to the public health systems. As of 15 April 2020, The Johns Hopkins University estimated that the COVID-19 affected more than two million people, resulting in a death toll above 130,000 around the world. Infected people in Europe and America correspond about 40% and 30% of the total reported cases respectively. At this moment only few Asian countries have controlled the disease, but a second wave of new infections is expected. Predicting inhibitor and target to the COVID-19 is an urgent need to protect human from the disease. Therefore, a protocol to identify anti-COVID-19 candidate based on computer-aided drug design is urgently needed. Thousands of compounds including approved drugs and drugs in the clinical trial are available in the literature. In practice, experimental techniques can measure the time and space average properties but they cannot be captured the structural variation of the COVID-19 during the interaction of inhibitor. Computer simulation is particularly suitable to complement experiments to elucidate conformational changes at the molecular level which are related to inhibition process of the COVID-19. Therefore, computational simulation is essential tool to elucidate the phenomenon. The structure-based virtual screening computational approach will be used to filter the best drugs from the literature, the investigate the structural variation of COVID-19 with the interaction of the best inhibitor is a fundamental step to design new drugs and vaccines which can combat the coronavirus. This mini-review will address novel coronavirus structure, mechanism of action, and trial test of antiviral drugs in the lab and patients with COVID-19.","J Biomol Struct Dyn","Boopathi, Subramanian","Poma, Adolfo B","Kolandaivel, Ponmalai","32306836"],"abstract":["In the past two decades, the world has faced several infectious disease outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms of economic disruption, the strain on local and global public health. Most recently, the global outbreak of novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 is a newly discovered virus from the coronavirus family in Wuhan city, China, known to be a great threat to the public health systems. As of 15 April 2020, The Johns Hopkins University estimated that the COVID-19 affected more than two million people, resulting in a death toll above 130,000 around the world. Infected people in Europe and America correspond about 40% and 30% of the total reported cases respectively. At this moment only few Asian countries have controlled the disease, but a second wave of new infections is expected. Predicting inhibitor and target to the COVID-19 is an urgent need to protect human from the disease. Therefore, a protocol to identify anti-COVID-19 candidate based on computer-aided drug design is urgently needed. Thousands of compounds including approved drugs and drugs in the clinical trial are available in the literature. In practice, experimental techniques can measure the time and space average properties but they cannot be captured the structural variation of the COVID-19 during the interaction of inhibitor. Computer simulation is particularly suitable to complement experiments to elucidate conformational changes at the molecular level which are related to inhibition process of the COVID-19. Therefore, computational simulation is essential tool to elucidate the phenomenon. The structure-based virtual screening computational approach will be used to filter the best drugs from the literature, the investigate the structural variation of COVID-19 with the interaction of the best inhibitor is a fundamental step to design new drugs and vaccines which can combat the coronavirus. This mini-review will address novel coronavirus structure, mechanism of action, and trial test of antiviral drugs in the lab and patients with COVID-19."],"journal":"J Biomol Struct Dyn","authors":["Boopathi, Subramanian","Poma, Adolfo B","Kolandaivel, Ponmalai"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32306836","week":"202017|Apr 20 - Apr 26","doi":"10.1080/07391102.2020.1758788","keywords":["ace2 receptor","covid-19","coronavirus","antiviral drugs","computational simulation","coronavirus spike"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["Wuhan","China","America"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664632501352529920,"score":154.88377}]}